Theralugand®
About:
Sterile [177Lu]Lutetium Chloride solution for radiolabeling.
Marketing Authorization:
Lutetium-177 Chloride Solution is regarded as a drug product in Europe and requires full registration to receive marketing authorization. Theralugand® has been registered in all countries of the European Economic Area (EEA).
Specifications:
-
[177Lu]Lutetium Chloride solution (clear and colorless)
-
[177Lu]Lutetium Chloride, 40 GBq/mL
-
Hydrochloric Acid (0.04 mol/L)
-
[177Lu]LuCl3 in 0.04 mol/L hydrochloric acid solution
-
As requested: 4 – 200 GBq per vial (activity tolerance ± 10%)
-
10 days after production
-
[ 177Lu]Lutetium can be produced to meet specific customer requirements for calibration date
-
10 days after production
-
> 99.0 % [177Lu]Lutetium as Lu3+
-
≥ 99,9%
[175Yb]Ytterbium ≤ 0.1%
[177mLu]Lutetium ≤ 0.07%
All other radionuclide impurities ≤ 0.01%
-
Max. 3 mL in a (3 mL) V-glass vial
Max. 5 mL in a 10R-glass flat bottom vial
Closure with crimp cap and pharma-grade stopper
-
1 - 2
-
< 20 EU/mL
-
Sterile
-
Within 4 business days worldwide
